Crude IRR | Adjusted IRR | 95% CI | p | ||
---|---|---|---|---|---|
Gender female vs male | 1.26 | 1.37 | 1.01 | 1.86 | 0.042 |
Age (effect per 10 years) | 0.88 | 0.95 | 0.86 | 1.05 | 0.302 |
Disease duration 5–9 vs <5 years | 0.92 | 0.67 | 0.48 | 0.93 | 0.016 |
Disease duration 10+ vs <5 years | 0.82 | 0.61 | 0.45 | 0.83 | 0.002 |
DMARDs + CS vs DMARDs^ | 0.87 | 0.76 | 0.34 | 1.68 | 0.493 |
Anti-TNFα vs DMARDs^ | 2.14 | 1.57 | 0.55 | 4.51 | 0.400 |
Anti-TNFα + CS vs DMARDs^ | 4.42 | 3.60 | 1.58 | 8.20 | 0.002 |
Anti-TNFα + DMARDs vs DMARDs^ | 2.92 | 2.11 | 0.95 | 4.71 | 0.067 |
Anti-TNFα + DMARDs + CS vs DMARDs^ | 3.24 | 2.54 | 1.15 | 5.59 | 0.021 |
Presence of comorbidities* and smoking | 1.22 | 1.07 | 0.85 | 1.37 | 0.554 |
Anti-influenza Vaccine | 0.84 | 0.73 | 0.57 | 0.94 | 0.016 |
Moderate Disease Activity vs Mild at baseline | 5.95 | 4.12 | 1.24 | 13.68 | 0.021 |
Severe Disease Activity vs Mild at baseline | 11.29 | 4.28 | 1.21 | 15.08 | 0.024 |
SpA vs RA | 0.91 | 0.96 | 0.67 | 1.38 | 0.817 |